SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study was to determine prospectively in all patients with SCLC in second line therapy that progression-free survival with the expected reintroduction of platinum / etoposide is greater progression-free survival in the standard arm (topotecan ) in patients who have relapsed at least three months after initial chemotherapy with platinum-etoposide
Epistemonikos ID: 8d6f3209ae05f4044d46ebd356eff8f5e3bd3463
First added on: May 12, 2024